financetom
Business
financetom
/
Business
/
Mohawk Industries posts lower third-quarter revenue on pressured pricing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Mohawk Industries posts lower third-quarter revenue on pressured pricing
Nov 3, 2024 11:14 AM

Home flooring manufacturer Mohawk Industries ( MHK ) reported a

lower third-quarter revenue on Thursday, hurt by pressured

pricing and weak demand for its flooring and ceramic products.

Shares of the Calhoun, Georgia-based company fell nearly 10%

after the bell.

"In all our regions, market conditions were slower than

anticipated given high interest rates, lingering inflation and

lower consumer confidence," CEO Jeff Lorberbaum said.

Mohawk, which operates in North America, Europe, Latin

America and Australasia, has reported $2.72 billion in revenue

for the quarter ended September 28, down 1.7% from last year.

Analysts had, on average, expected a revenue of $2.7

billion, according to data compiled by LSEG.

Home remodeling demand in the United States has decreased

due to higher borrowing costs and shrinking savings and are

squeezing wallets. The overall housing supply remains limited,

with residential construction activity subdued this year.

Sales at Mohawk's North America flooring segment, however,

rose 1.2% over a year, in contrast to the decline in its global

flooring and ceramic segments.

As the Federal Reserve starts to lower rates, the flooring

industry is projected to benefit next year due to an increase in

pent-up consumer demand for flooring purchases.

"We expect that recent interest rate cuts in the U.S.,

Europe and Latin America will strengthen housing markets and

increase flooring sales next year," Lorberbaum added.

Mohawk reported quarterly adjusted profit of $2.90 per

share, slightly above analysts' expectations of $2.89 per share.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Trump Media & Technology Shares Rise in Nasdaq Trading Debut
Trump Media & Technology Shares Rise in Nasdaq Trading Debut
Mar 26, 2024
09:49 AM EDT, 03/26/2024 (MT Newswires) -- Trump Media & Technology (DJT) was up more than 44% in recent Tuesday trading as it debuted on the Nasdaq following its merger with blank-check company Digital World Acquisition ( DWAC ). The operator of social media platform, Truth Social, had said earlier that the ticker symbol would switch from DWAC for its...
Blackstone eyes sale of Victor Allen's coffee owner Trilliant, sources say
Blackstone eyes sale of Victor Allen's coffee owner Trilliant, sources say
Mar 26, 2024
(Reuters) - Private equity firm Blackstone is considering a sale of Trilliant Food & Nutrition that could value the U.S. company behind the Victor Allen's and Aspen Ridge coffee brands at about $600 million including debt, three people familiar with the matter said. Blackstone has tapped Bank of America ( BAC ) as financial adviser on the potential sale, the...
EU targets Zoetis in antitrust investigation over dog medicines
EU targets Zoetis in antitrust investigation over dog medicines
Mar 26, 2024
(Reuters) - The European Commission on Tuesday said it had opened an antitrust investigation into possible breaches of EU competition rules by U.S. pet products maker Zoetis. The EU's executive said Zoetis was seen to have prevented the market launch of a novel biologic medicine used to treat chronic pain in dogs, which would have been a competitor for its...
Takeda Pharmaceutical Says Adzynma Gains Approval in Japan to Treat Blood Clotting Disorder
Takeda Pharmaceutical Says Adzynma Gains Approval in Japan to Treat Blood Clotting Disorder
Mar 26, 2024
09:44 AM EDT, 03/26/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Tuesday that the Japanese Ministry of Health, Labor and Welfare has approved Adzynma to treat congenital thrombotic thrombocytopenic purpura, a rare blood clotting disorder, in patients 12 years old and older. The approval was based on the company's data from an interim analysis of efficacy, pharmacokinetic, safety...
Copyright 2023-2026 - www.financetom.com All Rights Reserved